title: Temozolomide for recurrent or progressive high-grade malignant glioma: results of an Austrian multicenter observational study.
abstract: BACKGROUND
  The use of chemotherapy in patients with malignant gliomas has remained a controversial issue even after the publication of favorable study data and a meta-analysis. The present study was initiated to support the use of chemotherapy in patients with relapsed high-grade gliomas (HGG).
  
  
  METHODS
  Six Austrian centers recruited 43 patients with histologically confirmed HGG at first recurrence. Twelve chemotherapy-naïve patients received oral temozolomide at a dose of 200 mg/m(2) once a day for five consecutive days and 26 patients a dose of 150 mg/m(2) also for five days after various first-line chemotherapies. TMZ treatment was repeated every four weeks for a total of six cycles.
  
  
  RESULTS
  Twenty-one patients (52.5 %) received at least six cycles of therapy. Two patients experienced complete remission and eight patients a partial response. Twenty patients survived at one year after enrolment in the study; eight patients survived beyond three years of follow-up. Hematological toxicities consisted of three thrombocytopenias G4 and 35 lymphocytopenias G3 and G4; these did not cause interstitial pneumonia or require inpatient treatment. Non-hematological toxicities were rare and without clinical relevance. Patients' quality of life was maintained during treatment.
  
  
  CONCLUSIONS
  The study data confirm the feasibility and efficacy of chemotherapy with temozolomide in patients with relapsed/progressive HGG.
authors.affiliation: Department of Internal Medicine I, Clinical Division of Oncology, Medical University Vienna, Austria.
authors.forename: Marco
authors.initials: M
authors.lastname: Hassler
authors.forename: Michael
authors.initials: M
authors.lastname: Micksche
authors.forename: Günther
authors.initials: G
authors.lastname: Stockhammer
authors.forename: Josef
authors.initials: J
authors.lastname: Pichler
authors.forename: Franz
authors.initials: F
authors.lastname: Payer
authors.forename: Brigitte
authors.initials: B
authors.lastname: Abuja
authors.forename: Robert
authors.initials: R
authors.lastname: Deinsberger
authors.forename: Christine
authors.initials: C
authors.lastname: Marosi
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D018906:Antineoplastic Agents, Alkylating / Q000008:administration & dosage / Q000009:adverse effects; D001317:Austria / Q000453:epidemiology; D001932:Brain Neoplasms / Q000188:drug therapy* / Q000401:mortality*; D003606:Dacarbazine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D005260:Female; D005910:Glioma / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy / Q000401:mortality* / Q000517:prevention & control*; D011379:Prognosis; D018570:Risk Assessment / Q000379:methods*; D012307:Risk Factors; D015996:Survival Rate; D000077204:Temozolomide; D016896:Treatment Outcome
chemical_list: D018906:Antineoplastic Agents, Alkylating; D003606:Dacarbazine; D000077204:Temozolomide